FC

Frank Condella

Mayne Pharma Group Limited | Non-Executive Director, Non-Executive Chairman
Mr Condella is a US resident has over 30 years of experience in senior executive roles in the global pharmaceutical industry. His operating experience includes Chief Executive Officer of Juniper Pharmaceuticals, a US publicly-listed CDMO and specialty pharmaceutical company, which was subsequently sold to Catalent. Previously he served as Chief Executive Officer of Skyepharma Plc, President of European operations at IVAX (Teva), Chief Executive Officer of Faulding Pharmaceuticals, Vice President of Specialty Care Products at Roche and Vice President and General Manager of the Lederle Standard Products (Pfizer). Mr Condella's previous board experience includes Chairman of Skyepharma Plc until it merged with Vectura, Vice Chairman of Vectura Plc, Independent Director of Prosonix ltd, Independent Director of Fulcrum Pharma plc, Independent Director of Fertin Pharma A/S, Independent Director of Palladio Biosciences Inc and Chairman of the PKD Foundation. He is Chairman of People Commitee.

Company and Roles

Company
Title
Tenure
Since
MYX
Mayne Pharma Group Limited
  • Non-Executive Director
  • Non-Executive Chairman
6yrsMay 2018

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
MYX
Mayne Pharma Group Limited
01/12/2365,929N/AN/AN/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
MYX
Mayne Pharma Group Limited
01/12/23
Buy
7,154$5.425$38,811On-market trade
MYX
Mayne Pharma Group Limited
27/03/23
Buy
3,210$3.517$11,291On-market trade
MYX
Mayne Pharma Group Limited
24/03/23
Buy
17,788$3.524$62,691On-market trade
MYX
Mayne Pharma Group Limited
01/09/21
Buy
412,121$0.332$136,679On-market trade
MYX
Mayne Pharma Group Limited
01/09/20
Buy
110,696$0.337$37,287On-market trade